Preliminary phase II results of the CYPIDES study of ODM208 in metastatic castration-resistant prostate (mCRPC) cancer patients

被引：0
|
作者：
Fizazi, K. [1 ]
Bernard-Tessier, A. [1 ]
Barthelemy, P. [2 ]
Utriainen, T. [3 ]
Roubaud, G. [4 ]
Flechon, A. [5 ]
van der Voet, J. C. M. [6 ]
Mescam, G. Gravis [7 ]
Ratta, R. [8 ]
Jones, R. H. [9 ]
Parikh, O. A. [10 ]
Tanner, M. M. E. [11 ]
Garratt, C. [12 ]
Nevalaita, L. [13 ]
Pohjanjousi, P. [13 ]
Ikonen, T. [13 ]
Antonarakis, E. S. [14 ]
Cook, N. [15 ]
机构：
[1] Inst Gustave Roussy, Med Oncol, Villejuif, France
[2] ICANS Inst Cancerol, Med Oncol, Strasbourg, France
[3] Univ Helsinki, Oncol, Cent Hosp, Helsinki, Finland
[4] Inst Bergonie, Med Oncol, Bordeaux, France
[5] Ctr Leon Berard, Med Oncol, Lyon, France
[6] James Cook Univ Hosp, Radiotherapy, Middlesbrough, Cleveland, England
[7] IPC Inst Paoli Calmettes, Med Oncol, Marseille, France
[8] Hop Foch, Med Oncol, Suresnes, France
[9] NHS Wales, Velindre Canc Ctr, Cardiff, Wales
[10] Lancashire Teaching Hosp NHS Fdn Trust, Royal Preston Hosp, Oncol, Preston, Lancs, England
[11] Tampere Univ Hosp Tays, R&D, Tampere, Finland
[12] Orion Corp Orion Pharma, R&D, Newbury NG1 1AH, Berks, England
[13] Orion Corp Orion Pharma, R&D, Espoo, Finland
[14] Johns Hopkins Univ, Med Oncol, Baltimore, MD USA
[15] Christie NHS Fdn Trust, Med Oncol, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364MO
引用
收藏
页码：S1165 / S1165
页数：1
相关论文
共 50 条
  • [41] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Dorff, Tanya B.
    Quinn, David, I
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan
    Kuhn, Peter
    Gross, Mitchell E.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
  • [42] FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Zukotynski, Katherine A.
    Jadvar, Hossein
    Cho, Steve Y.
    Kim, Chun Ki
    Cline, Kathryn
    Emmenegger, Urban
    Hotte, Sebastien J.
    Pond, Gregory Russell
    Winquist, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [43] Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Karunaratna, Nathasha
    Jensen, Andrew
    Wong, Shirley
    Shapiro, Julia
    Weickhardt, Andrew
    Spain, Lavinia
    Azad, Arun
    Kwan, Edmond M.
    Muthusamy, Arun
    Torres, Javier
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey
    Gibbs, Peter
    Tran, Ben
    Anton, Angelyn
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 58 - 58
  • [44] Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Henriquez, Ivan
    Roach, Mack I. I. I. I. I. I.
    Morgan, Todd M.
    Bossi, Alberto
    Gomez, Junior A.
    Abuchaibe, Oscar
    Counago, Felipe
    BIOMEDICINES, 2021, 9 (09)
  • [45] Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.
    Clarke, Noel
    Wiechno, Pawel J.
    Alekseev, Boris
    Sala, Nuria
    Jones, Robert
    Kocak, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study
    Qin, Xiaojian
    Han, Weiqing
    Luo, Hong
    Du, Chuanjun
    Zou, Qing
    Sun, Zhongquan
    He, Chaohong
    Zhu, Shaoxing
    Chong, Tie
    Yao, Xin
    Wan, Ben
    Gu, Weijie
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [47] BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Carneiro, Benedito A.
    DeSouza, Andre
    Golijanin, Dragan
    Wood, Roxanne
    Olszewski, Adam J.
    Holder, Sheldon L.
    El-Deiry, Wafik S.
    Aggarwal, Rahul Raj
    Mega, Anthony E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [48] Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
    Dahut, William L.
    Madan, Ravi A.
    Karakunnel, Joyson J.
    Adelberg, David
    Gulley, James L.
    Turkbey, Ismail B.
    Chau, Cindy H.
    Spencer, Shawn D.
    Mulquin, Marcia
    Wright, John
    Parnes, Howard L.
    Steinberg, Seth M.
    Choyke, Peter L.
    Figg, William D.
    BJU INTERNATIONAL, 2013, 111 (08) : 1269 - 1280
  • [49] Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Rathkopf, Dana E.
    Danila, Daniel Costin
    Morris, Michael J.
    Slovin, Susan F.
    Steinbrecher, Jill Elise
    Arauz, Gabrielle
    Rix, Peter J.
    Maneval, Edna Chow
    Chen, Isan
    Fox, Josef J.
    Fleisher, Martin
    Larson, Steven M.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [50] Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
    Winquist, Eric
    Hotte, Sebastien J.
    Chi, Kim
    Sridhar, Srikala
    Ellard, Susan
    Ong, Michael
    Iqbal, Nayyer
    Salim, Muhammad
    Emmenegger, Urban
    Gingerich, Joel R.
    Lalani, Aly-Khan
    Major, Pierre
    Kollmannsberger, Christian
    Yip, Steven
    Hansen, Aaron
    Finch, Daygen
    Canil, Christina
    Hutchenreuther, James
    Vera-Badillo, Francisco
    Smoragiewicz, Martin
    Cabanero, Michael
    Tsao, Ming-Sound
    Ritch, Elie
    Wyatt, Alexander W.
    Seymour, Lesley
    CLINICAL CANCER RESEARCH, 2025, 31 (01) : 45 - 55
12345